Research programme: skin disorder therapeutics - Afecta Phamaceuticals/LEO Pharma
Latest Information Update: 28 Apr 2021
Price :
$50 *
At a glance
- Originator Afecta Pharmaceuticals; LEO Pharma
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Skin-disorders in Denmark
- 28 Apr 2021 No recent reports of development identified for research development in Skin-disorders in USA